stoxline Quote Chart Rank Option Currency Glossary
Gossamer Bio, Inc. (GOSS)
0.694  -0.036 (-4.93%)    05-17 16:00
Open: 0.74
High: 0.745
Volume: 955,712
Pre. Close: 0.73
Low: 0.69
Market Cap: 157(M)
Technical analysis
2024-05-17 4:46:01 PM
Short term     
Mid term     
Targets 6-month :  0.93 1-year :  1.05
Resists First :  0.79 Second :  0.9
Pivot price 0.73
Supports First :  0.63 Second :  0.52
MAs MA(5) :  0.72 MA(20) :  0.72
MA(100) :  0.99 MA(250) :  1
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  46 D(3) :  52.9
RSI RSI(14): 34.6
52-week High :  1.87 Low :  0.45
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GOSS ] has closed above bottom band by 9.5%. Bollinger Bands are 70.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.75 - 0.75 0.75 - 0.75
Low: 0.68 - 0.69 0.69 - 0.69
Close: 0.69 - 0.69 0.69 - 0.7
Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Headline News

Tue, 14 May 2024
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society ... - Business Wire

Mon, 13 May 2024
Gossamer Bio, Inc. Forecasted to Earn FY2028 Earnings of $0.24 Per Share (NASDAQ:GOSS) - MarketBeat

Mon, 13 May 2024
Wedbush Weighs in on Gossamer Bio, Inc.'s Q1 2025 Earnings (NASDAQ:GOSS) - Defense World

Fri, 10 May 2024
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Wed, 08 May 2024
Gossamer Bio: Q1 Earnings Snapshot - Houston Chronicle

Mon, 06 May 2024
Gossamer Bio Forms Major Alliance with Chiesi Farmaceutici - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 226 (M)
Shares Float 191 (M)
Held by Insiders 2.9 (%)
Held by Institutions 93.4 (%)
Shares Short 11,110 (K)
Shares Short P.Month 11,090 (K)
Stock Financials
EPS -1.18
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.28
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -37.2 %
Return on Equity (ttm) -480.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.77
Qtrly Earnings Growth 0 %
Operating Cash Flow -159 (M)
Levered Free Cash Flow -85 (M)
Stock Valuations
PE Ratio -0.59
PEG Ratio -0.4
Price to Book value 2.47
Price to Sales 0
Price to Cash Flow -0.99
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android